Advances in Pharmacogenomics

Pharmacogenomics is the study of the role of the genome in drug response. Its name (pharmaco- + genomics) reflects its combining of pharmacology and genomics. Pharmacogenomics analyzes how the genetic makeup of an individual affects his/her response to drugs. It deals with the influence of acquired and inherited genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with pharmacokinetics (drug absorption, distribution, metabolism, and elimination) and pharmacodynamics (effects mediated through a drug's biological targets). The term pharmacogenomics is often used interchangeably with pharmacogenetics. Although both terms relate to drug response based on genetic influences, pharmacogenetics focuses on single drug-gene interactions, while pharmacogenomics encompasses a more genome-wide association approach, incorporating genomics and epigenetics while dealing with the effects of multiple genes on drug response.

Components of the Book:
  • Chapter 1
    Clinical Genetics in Transition—a Comparison of Genetic Services in Estonia, Finland, and the Netherlands
  • Chapter 2
    Vcf2fhir: a Utility to Convert VCF Files into HL7 FHIR Format for Genomics‑EHR Integration
  • Chapter 3
    Discovery of Breast Cancer Risk Genes and Establishment of a Prediction Model Based on Estrogen Metabolism Regulation
  • Chapter 4
    Comorbidities and Inflammation Associated with Ovarian Cancer and Its Influence on SARS-CoV -2 Infection
  • Chapter 5
    Clinical Significance of HRAS and KRAS Genes Expression in Patients with Non– small-cell lung Cancer - Preliminary Findings
  • Chapter 6
    Communication of Pharmacogenomic Test Results and Treatment Plans in Pediatric Oncology: Deliberative Stakeholder Consultations with Parents
  • Chapter 7
    Multimorbidity, Polypharmacy, and Drugdrug- gene Interactions Following a Non-ST Elevation Acute Coronary Syndrome: Analysis of a Multicentre Observational Study
  • Chapter 8
    Mild Dyserythropoiesis and β-like Globin Gene Expression Imbalance Due to the Loss of Histone Chaperone ASF1B
  • Chapter 9
    PDXGEM: Patient-derived Tumor Xenograft-based Gene Expression Model for Predicting Clinical Response to Anticancer Therapy in Cancer Patients
  • Chapter 10
    Potential Pharmacogenomic Targets in Bipolar Disorder: Considerations for Current Testing and the Development of Decision Support Tools to Individualize Treatment Selection
  • Chapter 11
    Translating Insights from Neuropsychiatric Genetics and Genomics for Precision Psychiatry
  • Chapter 12
    An Epigenome-wide Association Study of Posttraumatic Stress Disorder in US Veterans Implicates Several New DNA Methylation Loci
  • Chapter 13
    TNF-α G-308A Genetic Variants, Serum CRP-hs Concentration and DNA Damage in Obese Women
  • Chapter 14
    Analysis of Neurodegenerative Diseasecausing Genes in Dementia with Lewy Bodies
  • Chapter 15
    Long-term Integrity Protection of Genomic Data
Readership: Students, academics, teachers and other people attending or interested in Pharmacogenomics
T. Vrijenhoek
Department of Genetics, University Medical Centre Utrecht, Utrecht, The Netherlands

Gillian Bartlett
Department of Family Medicine, McGill University, 5858 Chemin de la CÔtes-des-Neiges, Suite 300, Montreal, Quebec H3S 1Z1, Canada

Youngchul Kim
Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612-9416, USA.

Michał Ciebiera
II Department of Obstetrics and Gynecology, The Centre of Postgraduate Medical Education, Cegιowska 80, 01-809 Warsaw, Poland

Matthias Geihs
Technische Universitat Darmstadt, Department of Computer Science, Hochschulstrase 10, 64289 Darmstadt, Germany

and more...
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top